FDA found Healthtex Distributors' dietary supplements adulterated for CGMP failures and misbranded for labeling violations.
What happened
FDA inspected Healthtex's Miami dietary supplement warehouse and distribution facility on January 24, January 25, and February 1, 2023. The inspection found no written quality control procedures, no quality control operations, no holding and distribution procedures, and no identified person responsible for quality control. FDA also reviewed labels collected during the inspection and found the Dr. Sana Cod Liver Oil and Orange Blossom Flower Water labels misbranded, including undeclared ingredients and missing required Supplement Facts information.
What FDA found
Healthtex did not establish or follow written quality control procedures, including for material review and disposition decisions.
21 CFR 111.103 and 111.113Healthtex did not perform quality control operations such as approving and releasing its finished dietary supplements for distribution.
21 CFR 111.113Healthtex did not establish and follow written procedures for holding and distributing its dietary supplements.
21 CFR 111.453Healthtex did not identify who is responsible for its quality control operations.
21 CFR 111.12(b)The Dr. Sana Cod Liver Oil label did not declare Vitamin E and mineral oil as ingredients, and the Orange Blossom Flower Water label did not declare the individual ingredients in Orange Blossom Distillate Flower Water.
21 CFR 101.4(a) and (g); section 403(i)(2)The labels did not repeat all required information in both languages, the Cod Liver Oil Supplement Facts omitted calories, total fat, and vitamin D, and the products lacked required adverse event contact information, dietary supplement identity, or structure/function disclaimer as applicable.
21 CFR 101.15(c), 101.36, 101.3(g), and 101.93(b); sections 403(f), 403(q)(5)(F), 403(y), 403(s)(2)(B), and 403(r)(6)
What FDA wants
FDA asks Healthtex to notify it in writing within 15 working days of the specific steps taken to correct the violations, prevent recurrence, and provide related documentation. If corrective actions cannot be completed in that time, Healthtex must state why and when they will be completed.
Who should pay attention
- dietary supplement brands that use contract manufacturers or distributors
- warehouse and distribution firms holding dietary supplements
- label reviewers and regulatory compliance teams for supplement products
This is a summary. Read the original letter on fda.gov.